I think that’s a rhetorical question. If these shares are
so cheap at these prices then directors would surely
be loading up and they’re clearly not. They can’t even
offer any earnings guidance for the company. Speaks
volumes for the reality of Mayne’s predicament as I
keep mentioning….saw this with SGH years ago, heaps
of retails optimistic, but high debt nailed them, then private
equity came in and retails shares were virtually worthless.
If the company is so damned cheap where’s the TO offer
to put Mayne retails out of their misery??? Directors don’t
even want to put their hard earned in to this one, far better
to keep milking this thing for every dollar they can and investing
their hard earned in safer investments elsewhere. Bet that’s
what SR is doing but you can bet your bottom dollar that if
he’s run up margin loans…..again…..and he gets another margin
call when the markets start to tumble in earnest that he’ll be
a forced seller of Mayne not a purchaser. Doesn’t pay to put
all your eggs in the one basket unless that basket is a very
sound one with predictable earnings. Mayne does not fit into
that category hence it’s trading at historical lows despite all
the blue sky predictions. The market doesn’t trust SR and his
business plan with high debt. Reminds me of a high roller in the
mahogany room at Crown trying to win it all back after chasing
the losses of Teva to show everyone just how good a CEO he
really is….
- Forums
- ASX - By Stock
- MYX
- Ann: 2022 Half Year Investor Presentation
MYX
mayne pharma group limited
Add to My Watchlist
0.40%
!
$5.02

Ann: 2022 Half Year Investor Presentation, page-76
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.02 |
Change
0.020(0.40%) |
Mkt cap ! $407.8M |
Open | High | Low | Value | Volume |
$5.05 | $5.09 | $4.96 | $774.1K | 154.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3317 | $4.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.04 | 1291 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1317 | 4.990 |
1 | 1000 | 4.980 |
1 | 1000 | 4.960 |
1 | 1291 | 4.950 |
1 | 870 | 4.940 |
Price($) | Vol. | No. |
---|---|---|
5.040 | 1291 | 1 |
5.060 | 6210 | 4 |
5.080 | 1291 | 1 |
5.090 | 1100 | 2 |
5.100 | 1875 | 2 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online